GAITHERSBURG, Maryland, 29 mai 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), une entreprise mondiale qui fait progresser les vaccins à base de protéines avec son nouvel adjuvant Matrix-M™, a annoncé aujourd’hui que Nuvaxovid™ (NVX-CoV2373) a été recommandé pour une autorisation de…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.